Lapatinib and Trastuzumab With or Without Endocrine Therapy
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
We think that lapatinib will help to shrink your tumor when given prior to the main or
primary therapy for the kind of breast cancer you have been diagnosed with. When treatment is
given before the main or primary therapy, it is called neoadjuvant therapy. We will compare
lapatinib with lapatinib plus trastuzumab (herceptin) for 12 weeks. If your tumor is estrogen
receptor positive (ER positive), estrogen deprivation will also be given to you. Tumors that
are ER positive have a lot of estrogen receptors found in them. This is also called "over
expression" or amplification of estrogen receptors.
The most important information we will get from this study is to see the response to
"neoadjuvant" (treatment given before the main treatment), lapatinib with trastuzumab
(herceptin) in your tumor tissue sample.